Myers M G
Arch Intern Med. 1987 Jun;147(6):1026-30.
The blood pressure response to increasing doses of hydrochlorothiazide with or without amiloride was examined in 130 elderly hypertensive patients. After four weeks of placebo, patients were randomly allocated to increasing doses of hydrochlorothiazide or hydrochlorothiazide with amiloride for 12 weeks using a parallel, double-blind study design. Both hydrochlorothiazide and hydrochlorothiazide with amiloride significantly reduced mean (+/- SEM) baseline supine and standing blood pressure (171 +/- 2/102 +/- 1 and 167 +/- 2/102 +/- 1 mm Hg) to 148 +/- 2/84 +/- 1 and 146 +/- 3/85 +/- 1 mm Hg, respectively, at week 16. Amiloride did not exert any additional antihypertensive effect. Only eight patients required hydrochlorothiazide at 100 mg/d, with the remainder responding to 25 to 50 mg/d. Hydrochlorothiazide decreased mean serum potassium level from 4.3 +/- 0.1 mEq/L (4.3 +/- 0.1 mmol/L) during placebo to 4.0 +/- 0.1 mEq/L (4.0 +/- 0.1 mmol/L) at week 16. Ten patients receiving hydrochlorothiazide developed hypokalemia compared with only two receiving hydrochlorothiazide with amiloride. Relatively low doses of hydrochlorothiazide (25 to 50 mg/d) effectively reduce blood pressure in elderly hypertensive patients. Hypokalemia may occur with hydrochlorothiazide alone but is much less common when hydrochlorothiazide is combined with amiloride.
在130例老年高血压患者中,研究了增加氢氯噻嗪剂量(加或不加阿米洛利)时的血压反应。服用安慰剂四周后,采用平行双盲研究设计,将患者随机分配至接受递增剂量的氢氯噻嗪或氢氯噻嗪加阿米洛利治疗12周。氢氯噻嗪和氢氯噻嗪加阿米洛利均显著降低了平均(±标准误)基线仰卧位和站立位血压(分别为171±2/102±1和167±2/102±1 mmHg),在第16周时分别降至148±2/84±1和146±3/85±1 mmHg。阿米洛利未发挥任何额外的降压作用。仅8例患者需要100 mg/d的氢氯噻嗪,其余患者对25至50 mg/d的剂量有反应。氢氯噻嗪使平均血清钾水平从安慰剂期间的4.3±0.1 mEq/L(4.3±0.1 mmol/L)降至第16周时的4.0±0.1 mEq/L(4.0±0.1 mmol/L)。接受氢氯噻嗪治疗的10例患者发生了低钾血症,而接受氢氯噻嗪加阿米洛利治疗的患者仅有2例。相对低剂量的氢氯噻嗪(25至50 mg/d)可有效降低老年高血压患者的血压。单独使用氢氯噻嗪可能会发生低钾血症,但与阿米洛利合用时则不太常见。